Abide Therapeutics Appoints Dr. Gary O’Neill as Vice President of Biology

SAN DIEGO, Oct. 29, 2013 – Abide Therapeutics announces today that Gary O’Neill, Ph.D., has joined Abide Therapeutics as vice president of biology and member of the senior management team. Dr. O’Neill was previously discovery site head and vice president at Merck Research Laboratories in Boston, where he was responsible for Merck’s preclinical drug discovery programs in respiratory, immunology and …

Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases

SAN DIEGO, May 02, 2013 — Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic …

Abide and ActivX Complete Technology Agreement:

SAN DIEGO and PRINCETON, N.J, Dec. 12, 2012 — We are pleased to announce that Abide Therapeutics, Inc., San Diego CA, has entered into an agreement with ActivX Biosciences, Inc., La Jolla, CA, a leader in the field of activity based proteomics, granting Abide access to ActivX’s proprietary serine hydrolase technologies. ActivX, in conjunction with The Scripps Research Institute has …

Abide Therapeutics and SCYNEXIS, Inc. Collaborate In Finding Novel Anti-Viral and Anti-Parasitic Agents

RESEARCH TRIANGLE PARK, N.C. – SCYNEXIS, Inc. announced today that it has signed an agreement with Abide Therapeutics to collaborate in the search for novel anti-viral and anti-parasitic therapeutic compounds for human and animal health applications. Under the agreement, SCYNEXIS will screen, through its diverse biological screening platforms, Abide’s proprietary serine hydrolaseprotease inhibitor library with the objective of identifying compounds …